Radiation exposure assessment of nuclear medicine staff administering [177Lu]Lu-DOTA-TATE with active and passive dosimetry

被引:2
|
作者
Riveira-Martin, Mercedes [1 ,2 ]
Struelens, Lara [3 ]
Iglesias, Jose Munoz [4 ]
Schoonjans, Werner [3 ]
Tabuenca, Olga [4 ]
Nogueiras, Jose Manuel [5 ]
Gomez, Francisco Javier Salvador [6 ]
Medina, Antonio Lopez [6 ,7 ]
机构
[1] Galicia Hlth Res Inst IISGS, Genet Oncol Radiobiol & Radiointeract Res Grp, Vigo, Spain
[2] Univ Complutense Madrid, Med Sch, Dept Radiol Rehabil & Physiotherapy, Madrid, Spain
[3] Belgian Nucl Res Ctr SCK CEN, Mol, Belgium
[4] Univ Hosp Vigo, Meixoeiro Hosp, Nucl Med Dept SERGAS, Vigo, Spain
[5] Univ Hosp Vigo, Meixoeiro Hosp, Nucl Med Dept GALARIA, Vigo, Spain
[6] Univ Hosp Vigo, Meixoeiro Hosp, Med Phys & RP Dept GALARIA, Vigo, Spain
[7] Univ Vigo, Dept Funct Biol & Hlth Sci, Vigo, Spain
关键词
Lu-177]Lu-DOTA-TATE; Occupational exposure; Nuclear medicine; Equivalent dose; RECEPTOR RADIONUCLIDE THERAPY; NEUROENDOCRINE TUMORS; LU-177; SAFETY; LU-177-DOTATATE; LU-177-OCTREOTATE;
D O I
10.1186/s40658-023-00592-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: The use of lutetium-177 (Lu-177)-based radiopharmaceuticals in peptide receptor nuclear therapy is increasing, but so is the number of nuclear medicine workers exposed to higher levels of radiation. In recent years, [Lu-177]Lu-DOTA-TATE has begun to be widely used for the treatment of neuroendocrine tumours. However, there are few studies evaluating the occupational radiation exposure during its administration, and there are still some challenges that can result in higher doses to the staff, such as a lack of trained personnel or fully standardised procedures. In response, this study aims to provide a comprehensive analysis of occupational doses to the staff involved in the administration of [Lu-177]Lu-DOTA-TATE.Results: A total of 32 administrations of [Lu-177]Lu-DOTA-TATE (7.4 GBq/session) carried out by a physician and a nurse, were studied. In total, two physicians and four nurses were independently monitored with cumulative (passive) and/or real-time (active) dosemeters. Extremity, eye lens and whole-body doses were evaluated in terms of the dosimetric quantities Hp(0.07), Hp(3) and Hp(10), respectively. It was obtained that lead aprons reduced dose rates and whole-body doses by 71% and 69% for the physicians, respectively, and by 56% and 68% for the nurses. On average, normalised Hp(10) values of 0.65 +/- 0.18 mu Sv/GBq were obtained with active dosimetry, which is generally consistent with passive dosemeters. For physicians, the median of the maximum normalised Hp(0.07) values was 41.5 mu Sv/GBq on the non-dominant hand and 45.2 mu Sv/GBq on the dominant hand. For nurses 15.4 mu Sv/GBq on the non-dominant and 13.9 mu Sv/GBq on the dominant hand. The ratio or correction factor between the maximum dose measured on the hand and the dose measured on the base of the middle/ring finger of the non-dominant hand resulted in a factor of 5/6 for the physicians and 3/4 for the nurses. Finally, maximum normalised Hp(3) doses resulted in 2.02 mu Sv/GBq for physicians and 1.76 mu Sv/GBq for nurses.Conclusions: If appropriate safety measures are taken, the administration of [Lu-177]Lu-DOTA-TATE is a safe procedure for workers. However, regular monitoring is recommended to ensure that the annual dose limits are not exceeded.
引用
收藏
页数:25
相关论文
共 50 条
  • [21] Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE-A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
    Durma, Adam Daniel
    Saracyn, Marek
    Kolodziej, Maciej
    Jozwik-Plebanek, Katarzyna
    Dmochowska, Beata
    Kapusta, Waldemar
    Zmudzki, Wawrzyniec
    Mroz, Adrianna
    Kos-Kudla, Beata
    Kaminski, Grzegorz
    CANCERS, 2023, 15 (22)
  • [22] Efficacy of the personalized, dosimetry-based PRRT treatment of patients with neuroendocrine tumors using [177Lu]Lu-DOTA-TATE or [177Lu]/[90Y]Lu/Y-DOTA-TATE mixture - the DUONEN multicenter study
    Opalinska, M.
    Mikolajczak, R.
    Kaminski, G.
    Dedecjus, M.
    Kowalska, A.
    Kolodziej, M.
    Saracyn, M.
    Garnuszek, P.
    Cieszykowska, I.
    Sowa-Staszczak, A.
    Hubalewska-Dydejczyk, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S369 - S369
  • [23] Relationship between absorbed dose and response in neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE
    Warfvinge, C. F.
    Gustafsson, J.
    Roth, D.
    Tennvall, J.
    Svensson, J.
    Bernhardt, P.
    Akesson, A.
    Wieslander, E.
    Sundlov, A.
    Gleisner, Sjogreen K.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 221 - 221
  • [24] Personalized, dosimetry-based PRRT therapy in patients with neuroendocrine tumors using [177Lu]Lu-DOTA-TATE or [177Lu]Lu/[90Y]Y-DOTA-TATE mixture - the initial results of DUONEN multicenter study
    Opalinska, M.
    Kaminski, G.
    Dedecjus, M.
    Kowalska, A.
    Kolodziej, M.
    Saracyn, M.
    Gasior-Perczak, D.
    Lenda-Tracz, W.
    Sowa-Staszczak, A.
    Borkowska, A.
    Budzynska, A.
    Kubik, A.
    Chalewska, W.
    Kacperski, K.
    Szubstarska, P.
    Garnuszek, P.
    Mikolajczak, R.
    Hubalewska-Dydejczyk, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S314 - S314
  • [25] Renal Dosimetry in [177Lu]Lu-DOTA-TATE Therapy Based on Multiple Small VOIs as an Alternative to Whole-Kidney Segmentation
    Curkic, S.
    Gustafsson, J.
    Jessen, L.
    Ljungberg, M.
    Sundlov, A.
    Gleisner, K. Sjogreen
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S639 - S639
  • [26] Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
    Stenvall, Anna
    Gustafsson, Johan
    Larsson, Erik
    Roth, Daniel
    Sundlov, Anna
    Jonsson, Lena
    Hindorf, Cecilia
    Ohlsson, Tomas
    Gleisner, Katarina Sjogreen
    EJNMMI RESEARCH, 2022, 12 (01)
  • [27] Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
    Anna Stenvall
    Johan Gustafsson
    Erik Larsson
    Daniel Roth
    Anna Sundlöv
    Lena Jönsson
    Cecilia Hindorf
    Tomas Ohlsson
    Katarina Sjögreen Gleisner
    EJNMMI Research, 12
  • [28] Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
    Wehrmann, Christiane
    Senftleben, Stefan
    Zachert, Carolin
    Mueller, Dirk
    Baum, Richard P.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (03) : 406 - 416
  • [29] S-phase enrichment by hydroxyurea treatment enhances [177Lu]Lu-DOTA-TATE uptake in vitro
    Cheng, J.
    Livieratos, L.
    Terry, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S57 - S57
  • [30] Navigating nephrotoxicity: insights from 4 years of [177Lu]Lu-DOTA-TATE therapy at our institution
    Sousa, E.
    Sousa, R.
    Fraga, D.
    Carvalho, I. P.
    Vitorino, I.
    Rombo, D.
    Aco, J.
    Jorge, P.
    Salgado, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S667 - S667